Martina Fragni1, Sara Anna Bonini2, Armando Stabile3, Serena Bodei2, Luca Cristinelli4, Claudio Simeone4, Danilo Zani5, Pier Franco Spano2, Alfredo Berruti6, Maurizio Memo2, Sandra Sigala2. 1. Section of Pharmacology, Department of Molecular and Translational Medicine martina.fragni@unibs.it. 2. Section of Pharmacology, Department of Molecular and Translational Medicine. 3. Unit of Urology, Scientific Institute and University San Raffaele Hospital, Milan, Italy. 4. Urology Unit University of Brescia, Brescia, Italy. 5. Urology Unit University of Brescia, Brescia, Italy Division of Urology, City of Brescia Clinical Institute, Brescia, Italy. 6. Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Abstract
BACKGROUND/AIM: Evidence suggests that zoledronic acid (ZA) exerts direct antitumor effects on cancer cells but the underlying mechanisms of these actions are unknown. This study investigated the possible involvement of survivin in the antiproliferative effects of ZA in prostate cancer. MATERIALS AND METHODS: 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) dye reduction assay was used to assess cell viability and acridine orange/ethidium bromide double staining to analyze cell death. Human Apoptosis Array evaluated the expression of apoptosis-related proteins. Survivin protein was measured by western blot technique and miR-203 levels were quantified by quantitative real-time polymerase chain reaction. RESULTS: ZA induced inhibition of cell proliferation and apoptosis activation, with down-regulation of survivin protein. A negative regulation at gene expression level may be hypothesized because we observed a significant decrease of survivin mRNA level and an increase of miR-203 expression after ZA exposure. CONCLUSION: This study provides evidence that ZA may directly inhibit cancer cell proliferation, identifying survivin as one of its downstream targets. Copyright
BACKGROUND/AIM: Evidence suggests that zoledronic acid (ZA) exerts direct antitumor effects on cancer cells but the underlying mechanisms of these actions are unknown. This study investigated the possible involvement of survivin in the antiproliferative effects of ZA in prostate cancer. MATERIALS AND METHODS:3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) dye reduction assay was used to assess cell viability and acridine orange/ethidium bromide double staining to analyze cell death. Human Apoptosis Array evaluated the expression of apoptosis-related proteins. Survivin protein was measured by western blot technique and miR-203 levels were quantified by quantitative real-time polymerase chain reaction. RESULTS:ZA induced inhibition of cell proliferation and apoptosis activation, with down-regulation of survivin protein. A negative regulation at gene expression level may be hypothesized because we observed a significant decrease of survivin mRNA level and an increase of miR-203 expression after ZA exposure. CONCLUSION: This study provides evidence that ZA may directly inhibit cancer cell proliferation, identifying survivin as one of its downstream targets. Copyright
Authors: Elizabeth A Mazzio; Charles A Lewis; Rashid Elhag; Karam F Soliman Journal: Cancer Genomics Proteomics Date: 2018 Jul-Aug Impact factor: 3.395
Authors: Andy Göbel; Valentina M Zinna; Stefania Dell'Endice; Nikolai Jaschke; Jan Dominik Kuhlmann; Pauline Wimberger; Tilman D Rachner Journal: BMC Cancer Date: 2020-07-29 Impact factor: 4.430